Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074, Aachen, Germany; Department of Phytopathology, Justus-Liebig-University Giessen, Heinrich-Buff-Ring 26-32, 35392, Giessen, Germany.
LenioBio GmbH, Erkrather Straße 401, 40231, Düsseldorf, Germany.
J Plant Physiol. 2021 Mar-Apr;258-259:153359. doi: 10.1016/j.jplph.2020.153359. Epub 2021 Jan 5.
Recombinant proteins play an important role in many areas of our lives. For example, recombinant enzymes are used in the food and chemical industries and as high-quality proteins for research, diagnostic and therapeutic applications. The production of recombinant proteins is still dominated by expression systems based on microbes and mammalian cells, although the manufacturing of recombinant proteins in plants - known as molecular farming - has been promoted as an alternative, cost-efficient strategy for three decades. Several molecular farming products have reached the market, but the number of success stories has been limited by industrial inertia driven by perceptions of low productivity, the high cost of downstream processing, and regulatory hurdles that create barriers to translation. Here, we discuss the technical and economic factors required for the successful commercialization of molecular farming, and consider potential future directions to enable the broader application of production platforms based on plants.
重组蛋白在我们生活的许多领域发挥着重要作用。例如,重组酶被用于食品和化学工业,并作为高质量的蛋白质用于研究、诊断和治疗应用。尽管植物生产重组蛋白(称为分子农业)作为一种替代、具有成本效益的策略已经被推广了三十年,但基于微生物和哺乳动物细胞的表达系统仍然主导着重组蛋白的生产。已经有几种分子农业产品进入市场,但由于生产效率低、下游加工成本高以及监管障碍阻碍了转化等观念所导致的行业惰性,成功案例的数量有限。在这里,我们讨论了成功实现分子农业商业化所需的技术和经济因素,并考虑了潜在的未来方向,以能够更广泛地应用基于植物的生产平台。